Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis (FISTULA)
Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis
Sponsor: Baystate Medical Center
Listed as NCT03289520, this PHASE3 trial focuses on Hemodialysis Fistula Thrombosis and Kidney Failure and remains completed. Sponsored by Baystate Medical Center, it has been updated 9 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jan 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baystate Medical Center
- Boston University
- CAMC Health System
- Duke University
- Emory University
- MaineHealth
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- St. Louis University
- The Cleveland Clinic
- Tyler Nephrology Associates
- University of Alabama at Birmingham
- University of Iowa
- University of Texas Southwestern Medical Center
- Vanderbilt University
- Vascular Surgery Associates LLC
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .